We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
GSK plc | NYSE:GSK | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.16 | -0.41% | 38.66 | 39.115 | 38.61 | 39.04 | 3,851,914 | 01:00:00 |
30 March 2021, London, U.K.
GlaxoSmithKline plc (GSK)
GSK publishes respiratory product sales reporting
changes
|
Respiratory and HIV categories for reported sales to be
updated
To reflect the different stages of the product life-cycle of
certain respiratory products and to ensure consistency of reporting
for the sales of products with similar levels of strategic focus,
the reporting of Relvar/Breo
Ellipta along with the
smaller Incruse
Ellipta and Arnuity
Ellipta product sales will
with effect from the first quarter of 2021 be reported under the
"Established Respiratory" section of our "Established
Pharmaceuticals" category. Product sales
of Trelegy
Ellipta, Nucala and Anoro
Ellipta will continue to
be reported within the "Respiratory" category.
In addition, the reporting of sales of Epzicom/Kivexa and Selzentry will
going forward be incorporated into the "Other HIV" line within the
"HIV category".
The revised Pharmaceutical turnover tables below set out the
revised format for reporting Pharmaceutical product sales that will
be used from the first quarter 2021 results, in respect of the 2020
Pharmaceutical product sales.
An Excel version of this data is available
on www.gsk.com.
|
|
(GSK) - one of the world's
leading research-based pharmaceutical and healthcare companies - is
committed to improving the quality of human life by enabling people
to do more, feel better and live longer. For further
information please visit www.gsk.com
|
|
|
|
|
Analyst/Investor enquiries:
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
Brand names
Brand names appearing in italics throughout this document are
trademarks of GSK or associated companies or used under licence by
the Group.
This Announcement does not constitute statutory accounts of the
Group within the meaning of sections 434(3) and 435(3) of the
Companies Act 2006. The information for 2020 has been derived
from the full Group accounts published in the Annual Report
2020.
CER growth
In order to illustrate underlying performance, it is the Group's
practice to discuss its results in terms of constant exchange rate
(CER) growth. This represents growth calculated as if the exchange
rates used to determine the results of overseas companies in
Sterling had remained unchanged from those used in the comparative
period.
|
|
|
Registered
in England & Wales:
No. 3888792
|
|
|
|
Registered
Office:
980 Great West
Road
Brentford,
Middlesex
TW8 9GS
|
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
||||||||
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
||||
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
||||
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
2,360
|
31
|
32
|
1,486
|
28
|
30
|
548
|
28
|
27
|
326
|
53
|
56
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Anoro Ellipta
|
547
|
6
|
8
|
327
|
1
|
2
|
142
|
18
|
17
|
78
|
11
|
17
|
Trelegy Ellipta
|
819
|
58
|
59
|
561
|
47
|
48
|
168
|
65
|
65
|
90
|
>100
|
>100
|
Nucala
|
994
|
29
|
30
|
598
|
32
|
33
|
238
|
16
|
15
|
158
|
45
|
46
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
4,876
|
-
|
1
|
3,005
|
-
|
1
|
1,213
|
5
|
4
|
658
|
(5)
|
(1)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Dolutegravir products
|
4,702
|
1
|
2
|
2,941
|
-
|
1
|
1,163
|
7
|
6
|
598
|
(2)
|
3
|
Tivicay
|
1,527
|
(8)
|
(7)
|
871
|
(11)
|
(10)
|
368
|
(7)
|
(8)
|
288
|
(1)
|
5
|
Triumeq
|
2,306
|
(10)
|
(9)
|
1,454
|
(10)
|
(9)
|
568
|
(9)
|
(10)
|
284
|
(9)
|
(6)
|
Juluca
|
495
|
35
|
36
|
387
|
28
|
29
|
97
|
73
|
71
|
11
|
57
|
71
|
Dovato
|
374
|
>100
|
>100
|
229
|
>100
|
>100
|
130
|
>100
|
>100
|
15
|
>100
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rukobia
|
11
|
-
|
-
|
11
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cabenuva
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Other
|
163
|
(26)
|
(25)
|
53
|
(20)
|
(18)
|
50
|
(29)
|
(27)
|
60
|
(29)
|
(28)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-Inflammation and
Other Specialty
|
727
|
19
|
20
|
612
|
14
|
16
|
56
|
22
|
20
|
59
|
84
|
91
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Benlysta
|
719
|
17
|
19
|
612
|
14
|
16
|
56
|
22
|
20
|
51
|
59
|
66
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
372
|
62
|
62
|
231
|
72
|
74
|
136
|
42
|
40
|
5
|
-
|
-
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Zejula
|
339
|
48
|
48
|
206
|
54
|
55
|
128
|
35
|
33
|
5
|
-
|
-
|
Blenrep
|
33
|
-
|
-
|
25
|
-
|
-
|
8
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
New and Specialty Pharmaceuticals
|
8,335
|
11
|
12
|
5,334
|
10
|
12
|
1,953
|
13
|
12
|
1,048
|
12
|
16
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Pharmaceuticals
|
8,721
|
(13)
|
(12)
|
2,117
|
(18)
|
(17)
|
2,151
|
(10)
|
(11)
|
4,453
|
(12)
|
(9)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Established
Respiratory
|
4,640
|
(10)
|
(9)
|
1,676
|
(16)
|
(15)
|
1,134
|
(2)
|
(3)
|
1,830
|
(9)
|
(6)
|
Arnuity Ellipta
|
45
|
(6)
|
(6)
|
37
|
(10)
|
(7)
|
-
|
-
|
-
|
8
|
14
|
-
|
Avamys/Veramyst
|
297
|
(8)
|
(6)
|
-
|
-
|
-
|
66
|
(4)
|
(4)
|
231
|
(10)
|
(7)
|
Flixotide/Flovent
|
419
|
(33)
|
(32)
|
183
|
(50)
|
(50)
|
80
|
(9)
|
(10)
|
156
|
(10)
|
(5)
|
Incruse Ellipta
|
220
|
(16)
|
(15)
|
117
|
(27)
|
(27)
|
74
|
1
|
1
|
29
|
4
|
7
|
Relvar/Breo Ellipta
|
1,124
|
16
|
17
|
474
|
24
|
25
|
322
|
14
|
13
|
328
|
6
|
9
|
Seretide/Advair
|
1,535
|
(11)
|
(10)
|
434
|
(14)
|
(13)
|
449
|
(11)
|
(11)
|
652
|
(10)
|
(7)
|
Ventolin
|
785
|
(16)
|
(14)
|
430
|
(21)
|
(20)
|
116
|
(3)
|
(4)
|
239
|
(12)
|
(7)
|
Other Respiratory
|
215
|
(23)
|
(23)
|
1
|
>100
|
>100
|
27
|
(4)
|
-
|
187
|
(25)
|
(26)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
425
|
(4)
|
(1)
|
1
|
(67)
|
(67)
|
140
|
(12)
|
(13)
|
284
|
-
|
6
|
Augmentin
|
490
|
(19)
|
(15)
|
-
|
-
|
-
|
145
|
(16)
|
(16)
|
345
|
(20)
|
(15)
|
Avodart
|
466
|
(19)
|
(17)
|
5
|
25
|
25
|
158
|
(24)
|
(25)
|
303
|
(16)
|
(13)
|
Imigran/Imitrex
|
118
|
(14)
|
(14)
|
42
|
(29)
|
(29)
|
51
|
(2)
|
(4)
|
25
|
(7)
|
(4)
|
Lamictal
|
537
|
(5)
|
(4)
|
269
|
(5)
|
(5)
|
120
|
7
|
6
|
148
|
(13)
|
(9)
|
Seroxat/Paxil
|
146
|
(9)
|
(6)
|
-
|
-
|
-
|
37
|
-
|
(3)
|
109
|
(11)
|
(7)
|
Valtrex
|
103
|
(4)
|
(2)
|
15
|
7
|
7
|
32
|
3
|
-
|
56
|
(10)
|
(5)
|
Other
|
1,796
|
(21)
|
(20)
|
109
|
(48)
|
(47)
|
334
|
(28)
|
(28)
|
1,353
|
(16)
|
(14)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Pharmaceuticals
|
17,056
|
(3)
|
(1)
|
7,451
|
1
|
2
|
4,104
|
(1)
|
(1)
|
5,501
|
(9)
|
(5)
|
|
--------
|
--------
|
--------
|
--------
|
----------
|
--------
|
--------
|
---------
|
--------
|
--------
|
---------
|
--------
|
|
Pharmaceuticals turnover - three months ended 31 December
2020
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
||||||||
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
||||
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
||||
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
681
|
28
|
29
|
435
|
25
|
27
|
150
|
23
|
19
|
96
|
60
|
63
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Anoro Ellipta
|
151
|
7
|
8
|
90
|
(1)
|
1
|
39
|
18
|
15
|
22
|
29
|
29
|
Trelegy Ellipta
|
238
|
38
|
40
|
161
|
28
|
30
|
48
|
45
|
42
|
29
|
>100
|
>100
|
Nucala
|
292
|
34
|
34
|
184
|
39
|
42
|
63
|
13
|
7
|
45
|
50
|
53
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
1,268
|
1
|
2
|
805
|
3
|
5
|
327
|
10
|
6
|
136
|
(24)
|
(21)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Dolutegravir products
|
1,225
|
1
|
2
|
786
|
2
|
4
|
315
|
13
|
8
|
124
|
(23)
|
(19)
|
Tivicay
|
365
|
(14)
|
(13)
|
229
|
(6)
|
(4)
|
88
|
(12)
|
(17)
|
48
|
(41)
|
(35)
|
Triumeq
|
580
|
(9)
|
(9)
|
370
|
(9)
|
(7)
|
143
|
(7)
|
(10)
|
67
|
(13)
|
(13)
|
Juluca
|
139
|
25
|
25
|
108
|
21
|
22
|
28
|
47
|
37
|
3
|
-
|
33
|
Dovato
|
141
|
>100
|
>100
|
79
|
>100
|
>100
|
56
|
>100
|
>100
|
6
|
>100
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rukobia
|
8
|
-
|
-
|
8
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cabenuva
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Other
|
35
|
(29)
|
(20)
|
11
|
(21)
|
-
|
12
|
(33)
|
(22)
|
12
|
(29)
|
(35)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-Inflammation and
Other Specialty
|
206
|
21
|
24
|
175
|
18
|
21
|
15
|
25
|
17
|
16
|
60
|
70
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Benlysta
|
205
|
21
|
23
|
175
|
18
|
21
|
15
|
25
|
17
|
15
|
50
|
60
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
115
|
74
|
74
|
75
|
>100
|
>100
|
37
|
28
|
21
|
3
|
-
|
-
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Zejula
|
89
|
35
|
35
|
54
|
46
|
51
|
32
|
10
|
3
|
3
|
-
|
-
|
Blenrep
|
25
|
-
|
-
|
20
|
-
|
-
|
5
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
New and Specialty Pharmaceuticals
|
2,270
|
12
|
13
|
1,490
|
13
|
16
|
529
|
15
|
11
|
251
|
1
|
5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Pharmaceuticals
|
2,096
|
(17)
|
(16)
|
484
|
(25)
|
(23)
|
528
|
(10)
|
(13)
|
1,084
|
(17)
|
(15)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Established
Respiratory
|
1,092
|
(18)
|
(17)
|
373
|
(27)
|
(26)
|
278
|
(3)
|
(7)
|
441
|
(16)
|
(14)
|
Arnuity Ellipta
|
14
|
(7)
|
(13)
|
11
|
(15)
|
(8)
|
-
|
-
|
-
|
3
|
50
|
(50)
|
Avamys/Veramyst
|
70
|
(3)
|
(1)
|
-
|
-
|
-
|
15
|
-
|
-
|
55
|
(7)
|
(5)
|
Flixotide/Flovent
|
87
|
(53)
|
(52)
|
34
|
(70)
|
(69)
|
20
|
(9)
|
(18)
|
33
|
(33)
|
(29)
|
Incruse Ellipta
|
48
|
(38)
|
(38)
|
21
|
(60)
|
(58)
|
19
|
6
|
-
|
8
|
14
|
14
|
Relvar/Breo Ellipta
|
274
|
2
|
2
|
107
|
-
|
1
|
84
|
14
|
11
|
83
|
(6)
|
(3)
|
Seretide/Advair
|
351
|
(15)
|
(15)
|
73
|
(30)
|
(28)
|
105
|
(12)
|
(16)
|
173
|
(9)
|
(7)
|
Ventolin
|
211
|
(7)
|
(5)
|
125
|
1
|
3
|
29
|
(6)
|
(13)
|
57
|
(20)
|
(15)
|
Other Respiratory
|
37
|
(45)
|
(48)
|
2
|
>100
|
>100
|
6
|
(33)
|
(11)
|
29
|
(50)
|
(53)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
109
|
(3)
|
-
|
-
|
-
|
-
|
36
|
(10)
|
(12)
|
73
|
1
|
7
|
Augmentin
|
115
|
(27)
|
(24)
|
-
|
-
|
-
|
37
|
(21)
|
(26)
|
78
|
(30)
|
(23)
|
Avodart
|
96
|
(31)
|
(31)
|
1
|
>100
|
>100
|
34
|
(29)
|
(31)
|
61
|
(34)
|
(33)
|
Imigran/Imitrex
|
27
|
(23)
|
(26)
|
6
|
(60)
|
(60)
|
14
|
8
|
-
|
7
|
-
|
-
|
Lamictal
|
140
|
(3)
|
(3)
|
73
|
-
|
-
|
30
|
7
|
4
|
37
|
(16)
|
(11)
|
Seroxat/Paxil
|
36
|
(5)
|
(3)
|
-
|
-
|
-
|
10
|
11
|
-
|
26
|
(10)
|
(3)
|
Valtrex
|
26
|
(4)
|
(4)
|
4
|
-
|
-
|
8
|
-
|
(13)
|
14
|
(7)
|
-
|
Other
|
455
|
(18)
|
(17)
|
27
|
(27)
|
(16)
|
81
|
(25)
|
(25)
|
347
|
(15)
|
(14)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Pharmaceuticals
|
4,366
|
(4)
|
(3)
|
1,974
|
1
|
3
|
1,057
|
1
|
(3)
|
1,335
|
(14)
|
(12)
|
|
--------
|
--------
|
--------
|
--------
|
----------
|
--------
|
--------
|
---------
|
--------
|
--------
|
---------
|
--------
|
Pharmaceuticals turnover - nine months ended 30 September
2020
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
||||||||
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
||||
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
||||
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
1,679
|
32
|
33
|
1,051
|
30
|
31
|
398
|
30
|
31
|
230
|
50
|
53
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Anoro Ellipta
|
396
|
6
|
8
|
237
|
2
|
2
|
103
|
18
|
18
|
56
|
6
|
13
|
Trelegy Ellipta
|
581
|
68
|
69
|
400
|
56
|
57
|
120
|
74
|
75
|
61
|
>100
|
>100
|
Nucala
|
702
|
28
|
28
|
414
|
29
|
30
|
175
|
17
|
17
|
113
|
43
|
43
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
3,608
|
-
|
1
|
2,200
|
(1)
|
-
|
886
|
3
|
3
|
522
|
1
|
6
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Dolutegravir products
|
3,477
|
2
|
3
|
2,155
|
(1)
|
-
|
848
|
5
|
5
|
474
|
6
|
11
|
Tivicay
|
1,162
|
(6)
|
(5)
|
642
|
(12)
|
(12)
|
280
|
(5)
|
(5)
|
240
|
15
|
21
|
Triumeq
|
1,726
|
(10)
|
(9)
|
1,084
|
(10)
|
(9)
|
425
|
(10)
|
(10)
|
217
|
(8)
|
(4)
|
Juluca
|
356
|
40
|
41
|
279
|
30
|
31
|
69
|
86
|
89
|
8
|
100
|
100
|
Dovato
|
233
|
>100
|
>100
|
150
|
>100
|
>100
|
74
|
>100
|
>100
|
9
|
>100
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rukobia
|
3
|
-
|
-
|
3
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cabenuva
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Other
|
128
|
(26)
|
(26)
|
42
|
(19)
|
(23)
|
38
|
(27)
|
(29)
|
48
|
(29)
|
(26)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-Inflammation and
Other Specialty
|
521
|
18
|
19
|
437
|
13
|
14
|
41
|
21
|
21
|
43
|
95
|
100
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Benlysta
|
514
|
16
|
17
|
437
|
13
|
14
|
41
|
21
|
21
|
36
|
64
|
68
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
257
|
57
|
57
|
156
|
61
|
62
|
99
|
48
|
48
|
2
|
-
|
-
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Zejula
|
250
|
53
|
53
|
152
|
57
|
57
|
96
|
45
|
45
|
2
|
-
|
-
|
Blenrep
|
8
|
-
|
-
|
5
|
-
|
-
|
3
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
New and Specialty Pharmaceuticals
|
6,065
|
11
|
12
|
3,844
|
9
|
10
|
1,424
|
12
|
13
|
797
|
16
|
20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Pharmaceuticals
|
6,625
|
(12)
|
(10)
|
1,633
|
(15)
|
(15)
|
1,623
|
(10)
|
(10)
|
3,369
|
(11)
|
(7)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Established
Respiratory
|
3,548
|
(8)
|
(6)
|
1,303
|
(12)
|
(12)
|
856
|
(2)
|
(2)
|
1,389
|
(7)
|
(4)
|
Arnuity Ellipta
|
31
|
(6)
|
(3)
|
26
|
(7)
|
(7)
|
-
|
-
|
-
|
5
|
-
|
20
|
Avamys/Veramyst
|
227
|
(10)
|
(7)
|
-
|
-
|
-
|
51
|
(6)
|
(6)
|
176
|
(11)
|
(8)
|
Flixotide/Flovent
|
332
|
(25)
|
(23)
|
149
|
(41)
|
(41)
|
60
|
(9)
|
(8)
|
123
|
(1)
|
4
|
Incruse Ellipta
|
172
|
(7)
|
(6)
|
96
|
(12)
|
(12)
|
55
|
-
|
2
|
21
|
-
|
5
|
Relvar/Breo Ellipta
|
850
|
21
|
22
|
367
|
34
|
35
|
238
|
14
|
14
|
245
|
11
|
14
|
Seretide/Advair
|
1,184
|
(10)
|
(8)
|
361
|
(9)
|
(9)
|
344
|
(10)
|
(10)
|
479
|
(10)
|
(7)
|
Ventolin
|
574
|
(19)
|
(17)
|
305
|
(28)
|
(27)
|
87
|
(2)
|
(1)
|
182
|
(9)
|
(3)
|
Other Respiratory
|
178
|
(16)
|
(16)
|
(1)
|
-
|
-
|
21
|
11
|
5
|
158
|
(18)
|
(18)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
316
|
(5)
|
(2)
|
1
|
(67)
|
(67)
|
104
|
(13)
|
(13)
|
211
|
-
|
6
|
Augmentin
|
375
|
(16)
|
(12)
|
-
|
-
|
-
|
108
|
(14)
|
(13)
|
267
|
(16)
|
(12)
|
Avodart
|
370
|
(15)
|
(12)
|
4
|
-
|
-
|
124
|
(23)
|
(23)
|
242
|
(10)
|
(6)
|
Imigran/Imitrex
|
91
|
(12)
|
(11)
|
36
|
(18)
|
(18)
|
37
|
(5)
|
(5)
|
18
|
(10)
|
(5)
|
Lamictal
|
397
|
(6)
|
(4)
|
196
|
(7)
|
(6)
|
90
|
7
|
7
|
111
|
(12)
|
(8)
|
Seroxat/Paxil
|
110
|
(10)
|
(7)
|
-
|
-
|
-
|
27
|
(4)
|
(4)
|
83
|
(12)
|
(9)
|
Valtrex
|
77
|
(4)
|
(1)
|
11
|
10
|
10
|
24
|
4
|
4
|
42
|
(11)
|
(6)
|
Other
|
1,341
|
(23)
|
(21)
|
82
|
(52)
|
(53)
|
253
|
(29)
|
(29)
|
1,006
|
(16)
|
(13)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Pharmaceuticals
|
12,690
|
(2)
|
(1)
|
5,477
|
1
|
1
|
3,047
|
(1)
|
(1)
|
4,166
|
(7)
|
(3)
|
|
--------
|
--------
|
--------
|
--------
|
----------
|
--------
|
--------
|
---------
|
--------
|
--------
|
---------
|
--------
|
Pharmaceuticals turnover - three months ended 30 September
2020
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
||||||||
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
||||
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
||||
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
585
|
21
|
26
|
361
|
14
|
20
|
136
|
23
|
23
|
88
|
57
|
64
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Anoro Ellipta
|
140
|
(2)
|
3
|
86
|
(9)
|
(4)
|
35
|
17
|
13
|
19
|
-
|
21
|
Trelegy Ellipta
|
194
|
40
|
45
|
126
|
20
|
29
|
42
|
50
|
54
|
26
|
>100
|
>100
|
Nucala
|
251
|
24
|
29
|
149
|
25
|
32
|
59
|
11
|
11
|
43
|
39
|
45
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
1,216
|
(4)
|
-
|
755
|
(5)
|
-
|
296
|
1
|
1
|
165
|
(7)
|
1
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Dolutegravir products
|
1,176
|
(3)
|
1
|
739
|
(5)
|
-
|
284
|
3
|
4
|
153
|
(2)
|
5
|
Tivicay
|
377
|
(15)
|
(10)
|
220
|
(18)
|
(13)
|
87
|
(15)
|
(14)
|
70
|
(1)
|
7
|
Triumeq
|
577
|
(11)
|
(8)
|
368
|
(11)
|
(6)
|
135
|
(12)
|
(13)
|
74
|
(11)
|
(5)
|
Juluca
|
123
|
22
|
28
|
95
|
14
|
20
|
24
|
50
|
56
|
4
|
>100
|
100
|
Dovato
|
99
|
>100
|
>100
|
56
|
>100
|
>100
|
38
|
>100
|
>100
|
5
|
>100
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rukobia
|
3
|
-
|
-
|
3
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cabenuva
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Other
|
37
|
(34)
|
(32)
|
13
|
(24)
|
(24)
|
12
|
(33)
|
(39)
|
12
|
(43)
|
(33)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-Inflammation and
Other Specialty
|
193
|
13
|
18
|
158
|
5
|
11
|
15
|
25
|
25
|
20
|
>100
|
>100
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Benlysta
|
186
|
8
|
13
|
158
|
5
|
11
|
15
|
25
|
25
|
13
|
30
|
40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
99
|
55
|
58
|
61
|
61
|
68
|
36
|
35
|
35
|
2
|
>100
|
>100
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Zejula
|
92
|
44
|
47
|
57
|
50
|
55
|
33
|
27
|
27
|
2
|
>100
|
>100
|
Blenrep
|
8
|
-
|
-
|
5
|
-
|
-
|
3
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
New and Specialty Pharmaceuticals
|
2,093
|
5
|
10
|
1,335
|
2
|
8
|
483
|
9
|
9
|
275
|
14
|
21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Pharmaceuticals
|
2,099
|
(17)
|
(13)
|
583
|
(13)
|
(9)
|
491
|
(18)
|
(18)
|
1,025
|
(20)
|
(12)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Established
Respiratory
|
1,118
|
(11)
|
(6)
|
471
|
(8)
|
(3)
|
253
|
(8)
|
(8)
|
394
|
(17)
|
(9)
|
Arnuity Ellipta
|
14
|
17
|
33
|
13
|
30
|
30
|
-
|
-
|
-
|
1
|
(50)
|
50
|
Avamys/Veramyst
|
56
|
(15)
|
(8)
|
-
|
-
|
-
|
13
|
(13)
|
(13)
|
43
|
(16)
|
(6)
|
Flixotide/Flovent
|
92
|
(46)
|
(42)
|
45
|
(59)
|
(57)
|
15
|
(17)
|
(17)
|
32
|
(26)
|
(14)
|
Incruse Ellipta
|
56
|
(7)
|
(2)
|
33
|
(3)
|
3
|
16
|
(11)
|
(6)
|
7
|
(13)
|
(12)
|
Relvar/Breo Ellipta
|
323
|
30
|
34
|
169
|
64
|
70
|
73
|
3
|
1
|
81
|
8
|
15
|
Seretide/Advair
|
368
|
(12)
|
(8)
|
112
|
(4)
|
(1)
|
104
|
(14)
|
(14)
|
152
|
(16)
|
(8)
|
Ventolin
|
177
|
(23)
|
(18)
|
100
|
(26)
|
(22)
|
25
|
(7)
|
(4)
|
52
|
(24)
|
(15)
|
Other Respiratory
|
32
|
(40)
|
(28)
|
(1)
|
-
|
-
|
7
|
75
|
50
|
26
|
(46)
|
(38)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
110
|
(7)
|
(1)
|
-
|
-
|
-
|
36
|
(10)
|
(13)
|
74
|
(5)
|
5
|
Augmentin
|
106
|
(30)
|
(24)
|
-
|
-
|
-
|
30
|
(21)
|
(21)
|
76
|
(33)
|
(25)
|
Avodart
|
95
|
(37)
|
(30)
|
1
|
(50)
|
(50)
|
36
|
(29)
|
(29)
|
58
|
(40)
|
(30)
|
Imigran/Imitrex
|
30
|
(17)
|
(14)
|
11
|
(27)
|
(27)
|
12
|
(8)
|
(8)
|
7
|
(13)
|
-
|
Lamictal
|
125
|
(15)
|
(10)
|
61
|
(18)
|
(12)
|
30
|
(3)
|
(3)
|
34
|
(19)
|
(10)
|
Seroxat/Paxil
|
38
|
(10)
|
(2)
|
-
|
-
|
-
|
9
|
(10)
|
(10)
|
29
|
(9)
|
-
|
Valtrex
|
24
|
(14)
|
(7)
|
4
|
-
|
-
|
8
|
(11)
|
(11)
|
12
|
(20)
|
(7)
|
Other
|
453
|
(26)
|
(22)
|
35
|
(44)
|
(46)
|
77
|
(41)
|
(40)
|
341
|
(18)
|
(13)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Pharmaceuticals
|
4,192
|
(7)
|
(3)
|
1,918
|
(3)
|
2
|
974
|
(6)
|
(6)
|
1,300
|
(14)
|
(7)
|
|
--------
|
--------
|
--------
|
--------
|
----------
|
--------
|
--------
|
---------
|
--------
|
--------
|
---------
|
--------
|
Pharmaceuticals turnover - six months ended 30 June
2020
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
||||||||
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
||||
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
||||
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
1,094
|
40
|
38
|
690
|
40
|
37
|
262
|
34
|
35
|
142
|
46
|
46
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Anoro Ellipta
|
256
|
11
|
10
|
151
|
9
|
6
|
68
|
19
|
21
|
37
|
9
|
9
|
Trelegy Ellipta
|
387
|
87
|
85
|
274
|
81
|
77
|
78
|
90
|
90
|
35
|
>100
|
>100
|
Nucala
|
451
|
30
|
28
|
265
|
31
|
29
|
116
|
20
|
21
|
70
|
46
|
42
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
2,392
|
3
|
2
|
1,445
|
1
|
(1)
|
590
|
4
|
4
|
357
|
6
|
9
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Dolutegravir products
|
2,301
|
4
|
3
|
1,416
|
2
|
-
|
564
|
6
|
6
|
321
|
10
|
14
|
Tivicay
|
785
|
(1)
|
(2)
|
422
|
(9)
|
(11)
|
193
|
-
|
-
|
170
|
24
|
28
|
Triumeq
|
1,149
|
(9)
|
(10)
|
716
|
(9)
|
(11)
|
290
|
(9)
|
(9)
|
143
|
(6)
|
(3)
|
Juluca
|
233
|
51
|
49
|
184
|
40
|
38
|
45
|
>100
|
>100
|
4
|
100
|
100
|
Dovato
|
134
|
>100
|
>100
|
94
|
>100
|
>100
|
36
|
-
|
-
|
4
|
>100
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rukobia
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cabenuva
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Other
|
91
|
(22)
|
(23)
|
29
|
(17)
|
(23)
|
26
|
(24)
|
(24)
|
36
|
(23)
|
(23)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-Inflammation and
Other Specialty
|
328
|
21
|
19
|
279
|
18
|
16
|
26
|
18
|
18
|
23
|
77
|
77
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Benlysta
|
328
|
21
|
19
|
279
|
18
|
16
|
26
|
18
|
18
|
23
|
92
|
92
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
158
|
58
|
57
|
95
|
61
|
58
|
63
|
54
|
54
|
-
|
-
|
-
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Zejula
|
158
|
60
|
58
|
95
|
61
|
58
|
63
|
57
|
57
|
-
|
-
|
-
|
Blenrep
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
New and Specialty Pharmaceuticals
|
3,972
|
14
|
13
|
2,509
|
13
|
11
|
941
|
14
|
15
|
522
|
16
|
19
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Pharmaceuticals
|
4,526
|
(9)
|
(9)
|
1,050
|
(17)
|
(18)
|
1,132
|
(7)
|
(6)
|
2,344
|
(6)
|
(5)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Established
Respiratory
|
2,430
|
(6)
|
(6)
|
832
|
(15)
|
(16)
|
603
|
-
|
1
|
995
|
(3)
|
(1)
|
Arnuity Ellipta
|
17
|
(19)
|
(24)
|
13
|
(28)
|
(28)
|
-
|
-
|
-
|
4
|
33
|
-
|
Avamys/Veramyst
|
171
|
(8)
|
(7)
|
-
|
-
|
-
|
38
|
(3)
|
(3)
|
133
|
(10)
|
(8)
|
Flixotide/Flovent
|
240
|
(12)
|
(12)
|
104
|
(27)
|
(29)
|
45
|
(6)
|
(4)
|
91
|
12
|
14
|
Incruse Ellipta
|
116
|
(7)
|
(8)
|
63
|
(16)
|
(19)
|
39
|
5
|
5
|
14
|
8
|
15
|
Relvar/Breo Ellipta
|
527
|
16
|
16
|
198
|
16
|
14
|
165
|
20
|
20
|
164
|
13
|
14
|
Seretide/Advair
|
816
|
(9)
|
(9)
|
249
|
(11)
|
(12)
|
240
|
(8)
|
(8)
|
327
|
(8)
|
(6)
|
Ventolin
|
397
|
(17)
|
(17)
|
205
|
(29)
|
(30)
|
62
|
-
|
-
|
130
|
(2)
|
2
|
Other Respiratory
|
146
|
(8)
|
(11)
|
-
|
-
|
-
|
14
|
(7)
|
(7)
|
132
|
(9)
|
(12)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
206
|
(4)
|
(2)
|
1
|
(67)
|
(67)
|
68
|
(14)
|
(13)
|
137
|
3
|
6
|
Augmentin
|
269
|
(8)
|
(6)
|
-
|
-
|
-
|
78
|
(10)
|
(9)
|
191
|
(7)
|
(5)
|
Avodart
|
275
|
(3)
|
(3)
|
3
|
50
|
50
|
88
|
(19)
|
(19)
|
184
|
6
|
7
|
Imigran/Imitrex
|
61
|
(9)
|
(9)
|
25
|
(14)
|
(14)
|
25
|
(4)
|
(4)
|
11
|
(8)
|
(8)
|
Lamictal
|
272
|
(1)
|
(1)
|
135
|
(1)
|
(3)
|
60
|
13
|
13
|
77
|
(8)
|
(7)
|
Seroxat/Paxil
|
72
|
(10)
|
(10)
|
-
|
-
|
-
|
18
|
-
|
-
|
54
|
(13)
|
(13)
|
Valtrex
|
53
|
2
|
2
|
7
|
17
|
17
|
16
|
14
|
14
|
30
|
(6)
|
(6)
|
Other
|
888
|
(21)
|
(20)
|
47
|
(56)
|
(57)
|
176
|
(23)
|
(22)
|
665
|
(15)
|
(14)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Pharmaceuticals
|
8,498
|
-
|
-
|
3,559
|
3
|
1
|
2,073
|
2
|
2
|
2,866
|
(3)
|
(2)
|
|
--------
|
--------
|
--------
|
--------
|
----------
|
--------
|
--------
|
---------
|
--------
|
--------
|
---------
|
--------
|
Pharmaceuticals turnover - three months ended 30 June
2020
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
||||||||
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
||||
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
||||
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
574
|
30
|
27
|
378
|
34
|
30
|
122
|
17
|
18
|
74
|
32
|
27
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Anoro Ellipta
|
139
|
9
|
6
|
88
|
9
|
5
|
32
|
7
|
10
|
19
|
12
|
6
|
Trelegy Ellipta
|
194
|
62
|
58
|
140
|
65
|
60
|
36
|
64
|
59
|
18
|
38
|
46
|
Nucala
|
241
|
24
|
21
|
150
|
28
|
26
|
54
|
4
|
6
|
37
|
42
|
31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
1,185
|
(2)
|
(3)
|
740
|
1
|
(2)
|
270
|
(7)
|
(7)
|
175
|
(5)
|
(2)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Dolutegravir products
|
1,140
|
(1)
|
(2)
|
725
|
1
|
(2)
|
259
|
(4)
|
(5)
|
156
|
-
|
4
|
Tivicay
|
373
|
(9)
|
(10)
|
208
|
(14)
|
(16)
|
87
|
(12)
|
(14)
|
78
|
10
|
15
|
Triumeq
|
586
|
(9)
|
(11)
|
378
|
(6)
|
(9)
|
134
|
(16)
|
(16)
|
74
|
(12)
|
(10)
|
Juluca
|
113
|
35
|
33
|
90
|
29
|
27
|
21
|
62
|
62
|
2
|
100
|
>100
|
Dovato
|
68
|
>100
|
>100
|
49
|
>100
|
>100
|
17
|
-
|
-
|
2
|
>100
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rukobia
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cabenuva
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Other
|
45
|
(27)
|
(32)
|
15
|
(6)
|
(19)
|
11
|
(39)
|
(39)
|
19
|
(32)
|
(36)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-Inflammation and
Other Specialty
|
177
|
17
|
15
|
153
|
16
|
14
|
12
|
9
|
-
|
12
|
50
|
50
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Benlysta
|
177
|
18
|
15
|
153
|
16
|
14
|
12
|
9
|
-
|
12
|
71
|
71
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
77
|
35
|
33
|
47
|
42
|
39
|
30
|
25
|
21
|
-
|
-
|
-
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Zejula
|
77
|
35
|
32
|
47
|
42
|
39
|
30
|
25
|
21
|
-
|
-
|
-
|
Blenrep
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
New and Specialty Pharmaceuticals
|
2,013
|
8
|
6
|
1,318
|
11
|
9
|
434
|
2
|
1
|
261
|
5
|
6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Pharmaceuticals
|
2,089
|
(15)
|
(15)
|
483
|
(19)
|
(21)
|
497
|
(18)
|
(19)
|
1,109
|
(11)
|
(9)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Established
Respiratory
|
1,114
|
(9)
|
(9)
|
377
|
(15)
|
(17)
|
276
|
(7)
|
(8)
|
461
|
(4)
|
(2)
|
Arnuity Ellipta
|
8
|
(43)
|
(50)
|
6
|
(50)
|
(50)
|
-
|
-
|
-
|
2
|
-
|
(50)
|
Avamys/Veramyst
|
62
|
(13)
|
(10)
|
-
|
-
|
-
|
19
|
(5)
|
(10)
|
43
|
(16)
|
(10)
|
Flixotide/Flovent
|
117
|
(7)
|
(7)
|
54
|
(17)
|
(18)
|
17
|
(23)
|
(18)
|
46
|
18
|
18
|
Incruse Ellipta
|
59
|
4
|
2
|
33
|
6
|
-
|
19
|
-
|
-
|
7
|
-
|
14
|
Relvar/Breo Ellipta
|
242
|
2
|
2
|
83
|
(11)
|
(12)
|
78
|
11
|
9
|
81
|
8
|
12
|
Seretide/Advair
|
421
|
2
|
2
|
143
|
36
|
34
|
113
|
(12)
|
(13)
|
165
|
(7)
|
(6)
|
Ventolin
|
144
|
(39)
|
(39)
|
58
|
(59)
|
(60)
|
24
|
(17)
|
(21)
|
62
|
(6)
|
(2)
|
Other Respiratory
|
61
|
(10)
|
(16)
|
-
|
-
|
-
|
6
|
(25)
|
(12)
|
55
|
(10)
|
(16)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
95
|
(11)
|
(9)
|
1
|
-
|
-
|
30
|
(27)
|
(24)
|
64
|
(2)
|
-
|
Augmentin
|
100
|
(25)
|
(23)
|
-
|
-
|
-
|
21
|
(45)
|
(45)
|
79
|
(17)
|
(17)
|
Avodart
|
134
|
(5)
|
(6)
|
2
|
100
|
100
|
39
|
(26)
|
(28)
|
93
|
7
|
7
|
Imigran/Imitrex
|
27
|
(25)
|
(28)
|
10
|
(41)
|
(41)
|
12
|
(8)
|
(15)
|
5
|
(17)
|
(17)
|
Lamictal
|
135
|
(5)
|
(6)
|
66
|
(8)
|
(10)
|
28
|
-
|
(4)
|
41
|
(2)
|
(2)
|
Seroxat/Paxil
|
36
|
(10)
|
(10)
|
-
|
-
|
-
|
8
|
(11)
|
(11)
|
28
|
(10)
|
(10)
|
Valtrex
|
25
|
-
|
-
|
3
|
>100
|
>100
|
7
|
-
|
-
|
15
|
(12)
|
(12)
|
Other
|
423
|
(30)
|
(29)
|
24
|
(61)
|
(62)
|
76
|
(37)
|
(36)
|
323
|
(23)
|
(22)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Pharmaceuticals
|
4,102
|
(5)
|
(5)
|
1,801
|
1
|
(1)
|
931
|
(10)
|
(11)
|
1,370
|
(8)
|
(7)
|
|
--------
|
--------
|
--------
|
--------
|
----------
|
--------
|
--------
|
---------
|
--------
|
--------
|
---------
|
--------
|
Pharmaceuticals turnover - three months ended 31 March
2020
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
||||||||
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
||||
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
||||
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
520
|
52
|
52
|
312
|
49
|
47
|
140
|
54
|
55
|
68
|
66
|
73
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Anoro Ellipta
|
117
|
15
|
16
|
63
|
9
|
9
|
36
|
33
|
33
|
18
|
6
|
12
|
Trelegy Ellipta
|
193
|
>100
|
>100
|
134
|
>100
|
>100
|
42
|
>100
|
>100
|
17
|
>100
|
>100
|
Nucala
|
210
|
38
|
38
|
115
|
35
|
33
|
62
|
38
|
38
|
33
|
50
|
55
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
1,207
|
8
|
8
|
705
|
2
|
1
|
320
|
15
|
17
|
182
|
18
|
21
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Dolutegravir products
|
1,161
|
9
|
9
|
691
|
3
|
2
|
305
|
16
|
18
|
165
|
22
|
25
|
Tivicay
|
412
|
8
|
8
|
214
|
(4)
|
(5)
|
106
|
13
|
15
|
92
|
39
|
42
|
Triumeq
|
563
|
(8)
|
(8)
|
338
|
(12)
|
(13)
|
156
|
(3)
|
(1)
|
69
|
1
|
4
|
Juluca
|
120
|
71
|
69
|
94
|
54
|
51
|
24
|
>100
|
>100
|
2
|
100
|
100
|
Dovato
|
66
|
-
|
-
|
45
|
-
|
-
|
19
|
-
|
-
|
2
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rukobia
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cabenuva
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Other
|
46
|
(15)
|
(13)
|
14
|
(26)
|
(26)
|
15
|
(6)
|
(6)
|
17
|
(11)
|
(5)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-Inflammation and
Other Specialty
|
151
|
25
|
24
|
126
|
20
|
18
|
14
|
27
|
36
|
11
|
>100
|
>100
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Benlysta
|
151
|
25
|
24
|
126
|
20
|
18
|
14
|
27
|
36
|
11
|
>100
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
81
|
88
|
88
|
48
|
85
|
81
|
33
|
94
|
100
|
-
|
-
|
-
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Zejula
|
81
|
93
|
93
|
48
|
85
|
81
|
33
|
>100
|
>100
|
-
|
-
|
-
|
Blenrep
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
New and Specialty Pharmaceuticals
|
1,959
|
20
|
20
|
1,191
|
16
|
14
|
507
|
28
|
29
|
261
|
31
|
35
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Pharmaceuticals
|
2,437
|
(4)
|
(3)
|
567
|
(14)
|
(15)
|
635
|
5
|
6
|
1,235
|
(2)
|
(1)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Established
Respiratory
|
1,316
|
(4)
|
(4)
|
455
|
(14)
|
(15)
|
327
|
8
|
10
|
534
|
(1)
|
(1)
|
Arnuity Ellipta
|
9
|
29
|
29
|
7
|
17
|
17
|
-
|
-
|
-
|
2
|
100
|
100
|
Avamys/Veramyst
|
109
|
(5)
|
(5)
|
-
|
-
|
-
|
19
|
-
|
5
|
90
|
(6)
|
(7)
|
Flixotide/Flovent
|
123
|
(16)
|
(16)
|
50
|
(36)
|
(37)
|
28
|
8
|
8
|
45
|
7
|
10
|
Incruse Ellipta
|
57
|
(16)
|
(16)
|
30
|
(32)
|
(32)
|
20
|
11
|
11
|
7
|
17
|
17
|
Relvar/Breo Ellipta
|
285
|
33
|
32
|
115
|
47
|
45
|
87
|
30
|
33
|
83
|
19
|
16
|
Seretide/Advair
|
395
|
(19)
|
(18)
|
106
|
(40)
|
(40)
|
127
|
(5)
|
(3)
|
162
|
(8)
|
(7)
|
Ventolin
|
253
|
3
|
4
|
147
|
1
|
(1)
|
38
|
15
|
18
|
68
|
3
|
6
|
Other Respiratory
|
85
|
(7)
|
(8)
|
-
|
-
|
-
|
8
|
14
|
-
|
77
|
(8)
|
(8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
111
|
3
|
6
|
-
|
-
|
-
|
38
|
-
|
-
|
73
|
7
|
12
|
Augmentin
|
169
|
6
|
8
|
-
|
-
|
-
|
57
|
16
|
18
|
112
|
1
|
3
|
Avodart
|
141
|
(1)
|
-
|
1
|
-
|
-
|
49
|
(13)
|
(11)
|
91
|
6
|
7
|
Imigran/Imitrex
|
34
|
10
|
13
|
15
|
25
|
25
|
13
|
-
|
8
|
6
|
-
|
-
|
Lamictal
|
137
|
4
|
5
|
69
|
6
|
5
|
32
|
28
|
32
|
36
|
(14)
|
(12)
|
Seroxat/Paxil
|
36
|
(10)
|
(10)
|
-
|
-
|
-
|
10
|
11
|
11
|
26
|
(16)
|
(16)
|
Valtrex
|
28
|
4
|
4
|
4
|
(20)
|
(20)
|
9
|
29
|
29
|
15
|
-
|
-
|
Other
|
465
|
(10)
|
(9)
|
23
|
(51)
|
(51)
|
100
|
(6)
|
(7)
|
342
|
(6)
|
(4)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Pharmaceuticals
|
4,396
|
6
|
6
|
1,758
|
4
|
3
|
1,142
|
14
|
15
|
1,496
|
2
|
4
|
|
--------
|
--------
|
--------
|
--------
|
----------
|
--------
|
--------
|
---------
|
--------
|
--------
|
---------
|
--------
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: March
30, 2021
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions